Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2025-03-26
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of tislelizumab in
participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by
Progression-free Survival (PFS) as assessed by investigator